Mulligan, Mark J.

RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study

Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · New England Journal of Medicine

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies

Cited by 2,615

Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report

Mulligan, M. J., Lyke, K. E., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Raabe, V., Bailey, R., Swanson, K. A., et al. (2020) · Nature

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies

Cited by 1,569

Human Effector and Memory CD8+ T Cell Responses to Smallpox and Yellow Fever Vaccines

Miller, J. D., van der Most, R. G., Akondy, R. S., Glidewell, J. T., Albott, S., Masopust, D., Murali-Krishna, K., Mahar, P. L., Edupuganti, S., Lalor, S., et al. (2008) · Immunity

T-cell and B-cell ImmunologyImmunotherapy and Immune Responses

Cited by 601

Origin and differentiation of human memory CD8 T cells after vaccination

Akondy, R. S., Fitch, M., Edupuganti, S., Yang, S., Kissick, H. T., Li, K. W., Youngblood, B. A., Abdelsamed, H. A., McGuire, D. J., Cohen, K. W., et al. (2017) · Nature

T-cell and B-cell ImmunologyImmune responses and vaccinations

Cited by 517

The safety, immunogenicity, and acceptability of inactivated influenza vaccine delivered by microneedle patch (TIV-MNP 2015): a randomised, partly blinded, placebo-controlled, phase 1 trial

Rouphael, N. G., Paine, M., Mosley, R., Henry, S., McAllister, D. V., Kalluri, H., Pewin, W., Frew, P. M., Yu, T., Thornburg, N. J., et al. (2017) · The Lancet

Advancements in Transdermal Drug DeliveryInfluenza Virus Research Studies

Cited by 442

Systems analysis of immunity to influenza vaccination across multiple years and in diverse populations reveals shared molecular signatures

Nakaya, H. I., Hagan, T., Duraisingham, S. S., Lee, E. K., Kwissa, M., Rouphael, N., Frasca, D., Gersten, M., Mehta, A. K., Gaujoux, R., et al. (2015) · Immunity

Influenza Virus Research StudiesImmune responses and vaccinations

Cited by 337

Induction of broadly cross-reactive antibody responses to the influenza HA stem region following H5N1 vaccination in humans

Ellebedy, A. H., Krammer, F., Li, G.-M., Miller, M. S., Chiu, C., Wrammert, J., Chang, C. Y., Davis, C. W., McCausland, M., Elbein, R., et al. (2014) · Proceedings of the National Academy of Sciences

Influenza Virus Research Studiesvaccines and immunoinformatics approaches

Cited by 234

Broadly Neutralizing Activity of Zika Virus-Immune Sera Identifies a Single Viral Serotype

Dowd, K. A., DeMaso, C. R., Pelc, R. S., Speer, S. D., Smith, A. R. Y., Goo, L., Platt, D. J., Mascola, J. R., Graham, B. S., Mulligan, M. J., et al. (2016) · Cell Reports

Mosquito-borne diseases and controlViral Infections and Vectors

Cited by 206

Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities: A Randomized Clinical Trial

Cohen, M. S., Nirula, A., Mulligan, M. J., Novak, R. M., Marovich, M., Yen, C., Stemer, A., Mayer, S. M., Wohl, D., Brengle, B., et al. (2021) · JAMA

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies

Cited by 193

Neutralization of viruses with European, South African, and United States SARS-CoV-2 variant spike proteins by convalescent sera and BNT162b2 mRNA vaccine-elicited antibodies

Tada, T., Dcosta, B. M., Samanovic-Golden, M., Herati, R. S., Cornelius, A., Mulligan, M. J., & Landau, N. R. (2021) · mBio

SARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections Studies

Cited by 153

Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant

Lyke, K. E., Atmar, R. L., Islas, C. D., Posavad, C. M., Szydlo, D., Paul Chourdhury, R., Deming, M. E., Eaton, A., Jackson, L. A., Branche, A. R., et al. (2022) · Cell Reports Medicine

SARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections Studies

Cited by 153

The Spike Proteins of SARS-CoV-2 B.1.617 and B.1.618 Variants Identified in India Provide Partial Resistance to Vaccine-elicited and Therapeutic Monoclonal Antibodies

Tada, T., Zhou, H., Dcosta, B. M., Samanovic, M. I., Mulligan, M. J., & Landau, N. R. (2021) · iScience

SARS-CoV-2 and COVID-19 Researchvaccines and immunoinformatics approaches

Cited by 101

Partial resistance of SARS-CoV-2 Delta variants to vaccine-elicited antibodies and convalescent sera

Tada, T., Zhou, H., Dcosta, B. M., Samanovic, M. I., Mulligan, M. J., & Landau, N. R. (2021) · iScience

SARS-CoV-2 and COVID-19 Researchvaccines and immunoinformatics approaches

Cited by 101

B.1.526 SARS-CoV-2 Variants Identified in New York City are Neutralized by Vaccine-Elicited and Therapeutic Monoclonal Antibodies

Zhou, H., Dcosta, B. M., Samanovic, M. I., Mulligan, M. J., Landau, N. R., & Tada, T. (2021) · mBio

SARS-CoV-2 and COVID-19 Researchvaccines and immunoinformatics approaches

Cited by 68

Safety and Immunogenicity of Influenza A H5 Subunit Vaccines: Effect of Vaccine Schedule and Antigenic Variant

Belshe, R. B., Frey, S. E., Graham, I., Mulligan, M. J., Edupuganti, S., Jackson, L. A., Wald, A., Poland, G., Jacobson, R., Keyserling, H. L., et al. (2011) · The Journal of Infectious Diseases

Influenza Virus Research StudiesBacterial Infections and Vaccines

Cited by 62